DOCSLIB.ORG

Global Vaccine and Immunization Research Forum (GVIRF) 15 to 17 March 2016 Hilton Sandton Hotel, Johannesburg, South Africa

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Vaccine and Immunization Research Forum (GVIRF) 15 to 17 March 2016 Hilton Sandton Hotel, Johannesburg, South Africa Global Vaccine and Immunization Research Forum (GVIRF) 15 to 17 March 2016 Hilton Sandton Hotel, Johannesburg, South Africa PROVISIONAL LIST OF PARTICIPANTS Scientific Organizing Committee Dr Jean-Pierre Amorij, Chief Technology Officer & Founder, Virtuvax, Abcoude, Netherlands Dr Norman W. Baylor, President and Chief Executive Officer, Biologics Consulting Group, Inc., Alexandria, VA, USA Professor David Durrheim, Director of Health Protection, Hunter New England Area Health Service and Professor of Public Health, University of Newcastle, Eleebana, Australia Dr Thomas G. Evans, President and Chief Executive Officer, Aeras, Rockville, MD, USA (Unable to attend) Dr Ingileif Jonsdottir, Professor of Immunology, Department of Immunology, Landspitali, The University Hospital of Iceland, Reykjavik, Iceland (Unable to attend) Professor Gagandeep Kang, Professor and Head, The Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Tamil Nadu, Vellore, India (Unable to attend) Dr Rosanna Lagos, Coordinadora, Centro para vacunas en Desarollo-Chile, Hospital de Niños Roberto del Rio, Santiago, Chile (Unable to attend) Dr Odile Leroy, Executive Director, European Vaccine Initiative, Heidelberg, Germany Dr Kathleen Neuzil, Director, School of Medicine, University of Maryland, Center for Vaccine Development, Baltimore, Maryland , USA Dr Bernhards Ragama, Chief Research Officer, Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya Dr Alexander R Precioso, Director, Clinical Trials and Pharmacovigilance Division, Instituto Butantan, São Paulo SP, Brazil Professor Helen Rees, Executive Director, Wits Reproductive Health and HIV Research Institute, AFRO TFI Chair, University of Witwatersrand, Johannesburg, Gauteng, South Africa Dr Lucky Slamet, Technical Consultant for Badam Pom, Jakarta Selatan, Indonesia 1 | P a g e Participants Dr Salim Abdulla, Chief Executive Officer, Ifakara Health Institute, United Republic of Tanzania Dr Bernadette Abela-Ridder, Scientist, Neglected Zoonotic Diseases, World Health Organization, Geneva, Switzerland Dr Jon S. Abramson, Professor, Department of Pediatrics, Wake Forest Baptist Health, Winston-Salem, NC, USA Professor Bartholomew Akanmori, Regional Advisor, Vaccine Regulation, Immunization and Vaccine Development Programme, World Health Organization, Brazzaville, Republic of Congo Mr Alain Alsalhani, Pharmacist, Access Campaign, Médecins Sans Frontières, Paris, France Dr Kwasi Amfo, Vice President and Head, Global Dengue and EV71 Programs, Takeda Pharmaceutical Company Limited, Deerfield, Illinois, USA Dr William Kwabena Ampofo, Senior Research Fellow & Head, Virology, Noguchi Memorial Institute for Medical Research (NMIMR), Accra, Greater Accra, Ghana Dr Narendra Kumar Arora, Executive Director, The INCLEN Trust International, New Delhi, India Dr Deborah Atherly, Global Program Leader, Vaccine Access and Delivery, PATH, Seattle Washington, USA Dr Antoinette Ba-Nguz, Regional Coordinator, SIVAC Initiative, Agence de Médecine Préventive, Nairobi, Kenya Ms Katrine Bach Habersaat, Technical Officer, Vaccine-preventable Diseases and Immunization, World Health Organization, Regional Office for Europe, Copenhagen, Denmark Dr Shahida Baqar, Program Officer, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA Professor Alan Barrett, Director, Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA Professor Hyam N. Bashour, Professor of Epidemiology and Community Health, (EMRO TAG Chair), Faculty of Medicine, Damascus University, Damascus, Syria Ms Amie Batson, Chief, Strategy Officer, PATH, Seattle, Washington, USA Dr Seth Berkley, Chief Executive Officer, GAVI, the Vaccine Alliance, Geneva, Switzerland Dr Shyam Bishen, Deputy Director, Life Sciences Partnerships, Global Health, Bill & Melinda Gates Foundation, Seattle, Washington, USA 2 | P a g e Professor Lucille Blumberg, Deputy-Director, Head of Public Health Surveillance & Response, Division of Public Health, Surveillance and Response, National Institute for Communicable Diseases, South Africa Dr Kimberly Bonner, Medical Researcher, Access Campaign, Médecins sans Frontières / Doctors without borders, New York, NY, USA Dr Paula Bryant, Senior Scientist, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA Mr Kim Bush, Director, Life Sciences Partnerships, Bill & Melinda Gates Foundation, Seattle, Washington, USA Dr Robb Butler, Programme Manager, Vaccine Preventable Diseases and Immunization (VPI), World Health Organization, Regional Office for Europe, Copenhagen, Denmark Dr Marco Cavaleri, Executive Director & Head, Anti-Infectives and Vaccines, European Medicines Agency, London, UK Dr Thomas Cherian, Coordinator, Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland Dr Klaus Chichetuk, Director, Paul-Ehrlich-Institut, Langen, Germany Professor Nicola Christofides, Assistant Professor, Public Health, University of Witwatersrand, Johannesburg, South Africa Dr Ralf Clemens, Senior Vice President, GRID Rio, Rio de Janeiro, Brazil Dr Cheryl Cohen, Epidemiologist, National Institute for Communicable Diseases, Sandringham, South Africa Professor Tumani Corrah, Director, Africa Research Excellence Fundes, Africa Research Development Office, Medical Research Council, Banjul, Gambia Dr Ziyaad Dangor, Researcher, Respiratory and Meningeal Pathogens Research Unit, University of Witwatersrand, Soweto, South Africa Mrs Delese Mimi Darko, Acting Deputy Chief, Safety Monitoring and Clinical Trials Division, Food and Drugs Authority, Accra, Ghana Dr Michel De Wilde, Owner, MDWConsultant, LLC, Blairstown, NJ, USA Dr Carolyn Deal, Chief, Sexually Transmitted Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA Ms Heather Deehan, Chief, Vaccine Centre, Supply Division, UNICEF, Copenhagen, Denmark Professor Sinead Delany-Moretlwe, Research Director, Wits Reproductive Health & HIV Institute, University of Witwatersrand, Johannesburg, South Africa 3 | P a g e Dr Jane Deng, Associate Professor, Medicine - Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, California, USA Dr Laura Digilio, Deputy Director General, Development & Delivery Unit, International Vaccine Institute, SNU Research Park, Nakseongdae-dong, Gwanak-gu, Seoul, Republic of Korea Dr Dennis Dixon, Chief, Bacteriology and Mycology Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA Dr Maria Dominguez-Bello, Associate Professor, Department of Medicine, New York University School of Medicine, New York, NY, USA Dr Filip Dubovsky, Vice President, Clinical Development, Therapeutic Area Head, Department of Vaccines, MedImmune, Gaithersburg, Maryland, USA Dr Peter Dull, Deputy Director, Vaccine Development, Global Health Program, Bill & Melinda Gates Foundation, Seattle, Washington, USA Dr Rudi Eggers, Medical Officer, Immunization Systems Strengthening, Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland Professor Jose Esparza, Adjunct Professor, Department of Medicine, Institute of Human Virology, Reston, VA, USA Dr Lee Fairlie, Director, Child and Adolescent Health, WITS Reproductive Health & HIV Institute, University of Witwatersrand, Johannesburg, South Africa Dr Rebecca Fields, Senior Technical Advisor for Immunization, Maternal and Child Survival Program (MCSP), John Snow, Inc. JSI Research & Training Institute, Inc., Washington, D.C, USA Professor J. Peter Figueroa, Public Health, Epidemiology & AIDS, Department of Community Health & Psychiatry, University of the West Indies, Kingston , Jamaica Dr James Fleckenstein, Associate Professor, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA Dr Mark Andrew Fletcher, AFME & India Medical Lead, Pfizer Vaccines, Pfizer Inc., Paris, France Dr Andrew Ford, Scientific Program Analyst, Office of Scientific Coordination and Program Operations, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA Dr Martin Friede, Scientist, Technology Transfer initiative, World Health Organization, Geneva, Switzerland Dr Bernard Fritzell, Consultant, Paris, France Dr Bruce Gellin, Deputy Assistant Secretary for Health, Director, National Vaccine Program Office, Department of Health and Human Services, Washington, DC , USA Professor Armah George, Senior Research Fellow, Noguchi Medical Research Institute, Accra, Ghana 4 | P a g e Dr Birgitte Giersing, Technical Officer, Initiative for Vaccine Research, Immunization, Vaccines and Biologics, World Health Organization, Geneva, Switzerland Ms Susan Goldstein, Executive RM&E, Soul City: Institute for Health and Development Communication, Johannesburg, South Africa Dr James Goodson, Epidemiologist, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA Professor Barney S. Graham, Deputy Director, Vaccine Research Center, Chief, Viral Pathogenesis Laboratory and Translational Science Core, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland, USA Professor Glenda Gray, Chief Executive Officer President, South Africa Medical Research Council, Parktown, South Africa Mr Jan Grevendonk, Technical Officer,
Load more

Recommended publications
  • Leapfrogging Africa Sustainable Innovation in Health, Education and Agriculture
    Berlin Institute for Population and Development Leapfrogging Africa Sustainable Innovation in Health, Education and Agriculture hen in Rwanda bring in blood reserves +++ sustainable intensification makes farming more productive +++ online teaching not only during the pandemic +++ avoidable infectious diseases +++ kanian solutions +++ top school +++ development reduces the number of children +++ avoiding the mistakes of industrialized countries +++ central development areas: health, education and agriculture +++ Leapfrogging in Africa +++ higher yields +++ Diagnosis out of About the Berlin Institute The Berlin Institute for Population and Development is an independent think tank that deals with issues of regional and global demographic change. The Institute was founded in 2000 as a non-profit foundation and has the task of raising awareness of demographic change, promoting sustainable development, introducing new ideas into politics and developing concepts for solving demographic and development policy problems. In its studies, discussion and background papers, the Berlin Institute prepares scientific information for the political decision-making process. Further information, as well as the possibility to subscribe to the free regular newsletter “Demos”, can be found at www.berlin-institut.org. Support the independent work of the Berlin Institute. The Berlin Institute receives no public institutional support whatsoever. Project funding, research contracts, donations and endowments make the successful work of the Institute possible. The Berlin Institute is recognized as a non-profit organization. Donations and endowments are tax deductible. The Friends of the Berlin Institute brings together interested and committed individuals, companies and foundations who are willing to support the Berlin Institute financially and with ideas. You can find information about the Supporters’ Association at http://www.berlin-institut.org/foerderkreis-des-berlin-instituts.html.
    [Show full text]
  • Vaccine Hesitancy
    WHY CHILDREN WORKSHOP ON IMMUNIZATIONS ARE NOT VACCINATED? VACCINE HESITANCY José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA - Robert Koch Fellow, Robert Koch Institute, Berlin, Germany - Senior Advisor, Global Virus Network, Baltimore, MD, USA. Formerly: - Bill & Melinda Gates Foundation, Seattle, WA, USA - World Health Organization, Geneva, Switzerland The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) VACCINES VAILABLE TO PROTECT AGAINST MORE DISEASES (US) BASIC VACCINES RECOMMENDED BY WHO For all: BCG, hepatitis B, polio, DTP, Hib, Pneumococcal (conjugated), rotavirus, measles, rubella, HPV. For certain regions: Japanese encephalitis, yellow fever, tick-borne encephalitis. For some high-risk populations: typhoid, cholera, meningococcal, hepatitis A, rabies. For certain immunization programs: mumps, influenza Vaccines save millions of lives annually, worldwide WHAT THE WORLD HAS ACHIEVED: 40 YEARS OF INCREASING REACH OF BASIC VACCINES “Bill Gates Chart” 17 M GAVI 5.6 M 4.2 M Today (ca 2015): <5% of children in GAVI countries fully immunised with the 11 WHO- recommended vaccines Seth Berkley (GAVI) The goal: 50% of children in GAVI countries fully immunised by 2020 Seth Berkley (GAVI) The current world immunization efforts are achieving: • Equity between high and low-income countries • Bringing the power of vaccines to even the world’s poorest countries • Reducing morbidity and mortality in developing countries • Eliminating and eradicating disease WHY CHILDREN ARE NOT VACCINATED? •Vaccines are not available •Deficient health care systems •Poverty •Vaccine hesitancy (reticencia a la vacunacion) VACCINE HESITANCE: WHO DEFINITION “Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services.
    [Show full text]
  • TRANSLATING RECOMMENDATIONS INTO ACTION FIRST PROGRESS REPORT on IMPLEMENTATION of RECOMMENDATIONS November 2011–June 2012
    Commission on information and accountability for Women’s and Children’s Health TRANSLATING RECOMMENDATIONS INTO ACTION FIRST PROGRESS REPORT ON IMPLEMENTATION OF RECOMMENDATIONS November 2011–June 2012 Commission on information and accountability for Women’s and Children’s Health TRANSLATING RECOMMENDATIONS INTO ACTION FIRST PROGRESS REPORT ON IMPLEMENTATION OF RECOMMENDATIONS November 2011–June 2012 This is a preliminary report covering activities that have been carried out since November 2011, when the Strategic Workplan for Accountability (strategic workplan) was endorsed in a stake­ holders’ meeting in Ottawa, co­hosted by the Government of Canada and WHO. Working groups were formed to implement the strategic workplan. The first few months of work focused on institutional accountability processes by establishing national frameworks and global support activities. Results will become more apparent in the course of the upcoming implementation year. This report is prepared to inform the independent Expert Review Group for its progress report to the United Nations Secretary­General. © World Health Organization 2012 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e­mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Clinical Scholars Visit Amish Research Clinic in Lancaster County, PA by Patrick Brunner, MD Dr
    Spring 2018 Center for Clinical and Translational Science e- e-NewsletterNewsletter Center News James Krueger and Marina Caskey, Representing the Nussenzweig Lab Team, Honored at Translational Science 2018 Meeting By Hospital Leadership which fulfill the translation research Dr. James Krueger received paradigm of going from bench to the Association for Clinical and bedside, have been recognized by this Translational Science (ACTS) most prestigious national recognition. Distinguished Investigator Award for his It is well deserved!” Upon receiving the groundbreaking research on psoriasis at award, Dr. Krueger noted, “This award the Translational Science 2018 meeting would not have been possible without attended by more than 1,100 people in the support of many others associated Washington, DC in April. His research with the Rockefeller CTSA enterprise: has led to a fundamental change in my lab members, the nursing staff, the paradigm for understanding the all other support departments and, pathophysiology of the disorder, and of course, hundreds of patients who this in turn has led to the development directly tested progressively better drugs of a series of novel medications that that are now used to so effectively treat precisely modulate the immune system psoriasis.” and dramatically improve the therapy of the disorder. Each year, Clinical Research Forum sponsors a competition to identify Dr. Caskey Receiving “Top Ten” Award from the “Top Ten” Clinical Research Drs. Harry Selker and Herb Pardes studies reported in the previous year. commented that “The study reflects the The competition is intense and so it very best in translational science: the is a true tribute to the novelty and careful analysis of patient phenotypes; importance of the study led by Dr.
    [Show full text]
  • Tanzania National Institute for Medical Research TANZANIA Leonard Mboera
    ALIGNMENT AND HARMONISATION IN HEALTH RESEARCH COHRED Council on Health Research for Development Gabriela Montorzi Sylvia de Haan Carel IJsselmuiden Tanzania National Institute for Medical Research TANZANIA Leonard Mboera An assessment of the health research system A country report of the AHA series Council on Health Research for Development (COHRED) ALIGNMENT AND HARMONISATION IN HEALTH RESEARCH COHRED TANZANIA An assessment of the health research system A country report of the AHA series Council on Health Research for Development Gabriela Montorzi Sylvia de Haan Carel IJsselmuiden Tanzania National Institute for Medical Research Leonard Mboera Council on Health Research for Development (COHRED) Acknowledgements We are grateful to all our collaborators for contributing in different ways to the successful completion of this study. Thanks are due to: • NACCAP for providing the financial support for this study. • All stakeholders interviewed, for their availability and valuable contribution to the understanding of the Tanzania Health Research System. • Donor agency headquarters for validating financial data and contributing with financial information. Keywords Alignment and harmonisation, national health research systems, Tanzania, Canada, Denmark, Ireland, The Netherlands, Norway, Sweden, Switzerland, United Kingdom, Paris declaration on aid effectiveness, research financing ISBN 92-9226-034-0 Copyright and Fair Use The Council on Health Research for Development (COHRED) holds the copyright to its publications and web pages but encourages duplication and dissemination of these materials for non-commercial purposes. Proper citation is requested and modification of these materials is prohibited. Permission to make digital or hard copies of part or all of this work for personal or classroom use is granted without fee and without a formal request provided that copies are not made or distributed for profit or commercial purposes and that copies bear this notice and full citation on the first page.
    [Show full text]
  • Report on Global Surveillance of Epidemic-Prone Infectious Diseases, 2000
    Pan American Health Organization Regional Office of the World Health Organization PAHO/DPC/CD-V/243/03 Original: English Report: Workshop on Dengue Burden Studies (Washington, DC, 5-7 November 2002) Convened by The Pan American Health Organization The Rockefeller Foundation The Pediatric Dengue Vaccine Initiative Executive Summary Background Dengue fever (DF) and dengue hemorrhagic fever (DHF) are caused by the mosquito borne virus, dengue virus, of which there are four antigenically distinct serotypes. It is estimated that annually these viruses cause at least 20 million infections worldwide leading to some 24,000 deaths (WHO, http://www.who.int/health_topics/dengue/en/ ). The alarming rise in dengue hemorrhagic fever in the world today is illustrated most starkly by the chart below which represents data from the World Health Organization (WHO) showing the rise of DHF cases over the last four decades. Indeed the first two years of the new millennium has seen outbreak after outbreak of DHF not only in Southeast Asia where DHF has been seen for half a century, but also in many countries of South and Central America. REPORTED CASES OF DHF 600 ds 500 housan t 400 n d i e 300 200 r report e 100 numb 0 1955-1959 1960-1069 1970-1979 1980-1989 1990-1998 Source: WHO; adapted from http://www.who.int/health_topics/dengue/en/ While there is no doubt that severe dengue is spreading from countries in Southeast Asia to countries in the Pacific and in the Americas, there is also no doubt that many international efforts into the development of dengue vaccines have led to a number of promising vaccine candidates which may offer some solutions to the control of this disease.
    [Show full text]
  • Ethical Implications of Malaria Vaccine Development
    Institute of Biomedical Ethics and History of Medicine, University of Zurich Director: Prof. Dr. med. Dr. phil. Nikola Biller-Andorno ______________________________________________________________________ Dissertation under the supervision of Prof. Dr. med. Dr. phil. Nikola Biller-Andorno and Prof. Dr. phil. Marcel Tanner Ethical Implications of Malaria Vaccine Development INAUGURAL-DISSERTATION To receive the title of (Dr. sc. med./PhD) awarded by the Faculty of Medicine University of Zurich submitted by Machteld van den Berg Dissertation committee: Prof. Dr. med. Dr. phil. Nikola Biller-Andorno (chair and main supervisor) Prof. Dr. phil. Marcel Tanner (co-supervisor) PD Dr. med. et sc. nat. Sonja Merten This dissertation has been accepted by the Medical Faculty, University of Zurich upon request of Prof. Dr. Dr. Nikola Biller- Andorno Zurich 2019 Publication record These dissertation chapters have been published/submitted in/to the following journals: 1. RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials Machteld van den Berg, Bernhards Ogutu, Nelson Sewankambo, Nikola Biller-Andorno, Marcel Tanner Published: May 2019 Journal: BMC Trials 2. Clinical trials in low-resource settings: the perspectives of caregivers of paediatric participants from Uganda, Tanzania and Kenya Machteld van den Berg, Bernhards Ogutu, Nelson Sewankambo, Sonja Merten, Nikola Biller-Andorno, Marcel Tanner Published: June 2019 Journal: Tropical Medicine & International Health 3. Applying complexity theory to model
    [Show full text]
  • 5.09 Otras Ciencias Sociales
    CONICYT Ranking por Disciplina > Sub-área OECD (No Académicas) Comisión Nacional de Investigación 5. Ciencias Sociales > 5.9 Otras Ciencias Sociales Científica y Tecnológica PAÍS INSTITUCIÓN RANKING PUNTAJE FRANCE Centre National de la Recherche Scientifique (CNRS) 1 5,000 USA University of Illinois Chicago Hospital 2 5,000 GERMANY Max Planck Society 3 5,000 TAIWAN Academia Sinica - Taiwan 4 5,000 CANADA Centre for Addiction & Mental Health - Canada 5 5,000 USA Centers for Disease Control & Prevention - USA 6 5,000 USA VA Boston Healthcare System 7 5,000 ITALY Consiglio Nazionale delle Ricerche (CNR) 8 5,000 CHINA Chinese Academy of Sciences 9 5,000 SPAIN Consejo Superior de Investigaciones Cientificas (CSIC) 10 5,000 NORWAY Institute of Transport Economics 11 5,000 USA National Bureau of Economic Research 12 5,000 RUSSIA Russian Academy of Sciences 13 5,000 ARGENTINA Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) 14 5,000 CZECH REPUBLIC Czech Academy of Sciences 15 5,000 FRANCE Institut National de la Sante et de la Recherche Medicale (Inserm) 16 5,000 USA Microsoft 17 5,000 USA National Institutes of Health (NIH) - USA 18 5,000 USA Research Triangle Institute 19 5,000 USA Atlanta VA Health Care System 20 5,000 USA US Department of Veteran Affairs 21 5,000 NETHERLANDS Academic Medical Center Amsterdam 22 5,000 USA New York State Psychiatry Institute 23 5,000 GERMANY IZA Institute Labor Economics 24 5,000 GERMANY Helmholtz Association 25 5,000 ROMANIA Romanian Academy of Sciences 26 5,000 UNITED KINGDOM NERC Natural
    [Show full text]
  • Comparison of Clinical Trials in the Industrialized World and Africa Christian Burri; Swiss Tropical and Public Health Institute
    Life Science Forum Basel 2010 Comparison of Clinical Trials in the industrialized world and Africa Christian Burri; Swiss Tropical and Public Health Institute Department of Medicines Research Basel, 23rd June 2010 Comparison of Clinical Trials in the industrialized world and Africa Life Science Forum Basel PD Dr. Christian Burri Head of Department Swiss Tropical & Public Health Institute The Swiss TPH … … is an associated institute of the University of Basel … has the mandate to contribute to the improvement of the health of populations internationally and nationally through excellence in research, services, and teaching & training at the levels of innovation, validation & application … has over 500 staff from 40 nations thereof ~100 PhD students 1 Life Science Forum Basel 2010 Comparison of Clinical Trials in the industrialized world and Africa Christian Burri; Swiss Tropical and Public Health Institute Swiss Tropical & Public Health Institute The Swiss TPH … … the Swiss Tropical Institute (STI) was founded in 1943 as a public organisation based on a local government act … became the “Swiss Tropical and Public Health Institute” (Swiss TPH) at the beginning of the year 2010 after the integration of the Institute of Social & Preventive Medicine (ISPM) of the University of Basel … is supported at ~20 % by the Swiss Federal Government & Canton of Basel- Stadt … earns the greater part of funding through competitively acquired project funds and the earnings of the Service Departments Agenda • Contribution by the Swiss Tropical & Public Health
    [Show full text]
  • V21 MTG 0033 List of Particip
    THE FIRST WHO INTEGRATED MEETING ON DEVELOPMENT AND CLINICAL TRIALS OF INFLUENZA VACCINES THAT INDUCE BROADLY PROTECTIVE AND LONG-LASTING IMMUNE RESPONSES Baptist University, Hong Kong 24 – 26 January 2013 LIST OF PARTICIPANTS Dr Akira Ainai, Emeritus Member, National Institute of Infectious Diseases, Tokyo, Japan Dr Christopher Ambrose, Senior Director, Medical Affairs, MedImmune, Gaithersburg, United States of America Professor Filippo Ansaldi, Health Sciences, University of Genoa and Hygiene Unit, Genoa, Italy Dr Robert L. Atmar, Associate Professor, Department of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, United States of America Dr Emma Ball, CSL Limited A.C.N., Parkville, Victoria, Australia Dr Pamuk Bilsel, FluGen Inc., Madison, United States of America Mr Albert Chan, President, Hong Kong Baptist University, Hong Kong, China Dr Paul Chan, Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China Dr Marta Coehlo Nunes, Respiratory and Meningeal Pathogens Research Unit, Wits University, Johannesburg, South Africa Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China Dr Manon Cox, President and CEO, Protein Sciences Corporation, Meridien, United States of America Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, Bergen, 5021 Norway Dr Giuseppe Del Giudice, Global Head Translation Medicine, Novartis Vaccines and Diagnostics S.p.A, Divisione Biologici
    [Show full text]
  • 5Th Annual Short Course in Medical Virology Baltimore, MD August 5-11
    5th Annual Short Course in Medical Virology Baltimore, MD ǀ August 5-11, 2018 ǀ Program Locations: IHV ǀ Baltimore JH ǀ Baltimore NIH ǀ Bethesda Sunday, August 5 3:00 PM Hotel Check In 6:00-8:00 PM Short Course Opening Dinner at Diamond Tavern Monday, August 6 9:00-10:00 AM Shyam Kottilil, MD, PhD, Institute of Human Virology "Hepatitis C" 10:00-10:15 AM Coffee break 10:15- 11:15 AM Yutaka Tagaya, MD, PhD, Institute of Human Virology "Human T-cell leukemia virus-1, an exceptionally oncogenic retrovirus" 11:15-12:15 PM Robert Gallo, MD, Institute of Human Virology "Human Retroviruses: HTLV and HIV: an Overview” 12:15- 1:15 PM group picture & lunch 1:15-2:15 PM Jose Esparza, MD, PhD, Institute of Human Virology "Vaccines" 2:15-3:15 PM Alfredo Garzino-Demo, PhD, Institute of Human Virology "HIV Pathogenesis" 3:15-3:30 PM Coffee break 3:30- 4:30 PM Neil Constantine, PhD, Insitute of Human Virology "Laboratory diagnostics" Tuesday, August 7 8:15 AM Transportation to Johns Hopkins Bloomberg School of Public Health 9:00-10:00 AM Diane Griffin, PhD, MD, Johns Hopkins Bloomberg School of Public Health "Measles" 10:00-11:00 AM Ken Olson, PhD, Colorado State University "Arboviruses" 11:00-11:30 AM Break 11:30-12:30 AM Marcelo Jacobs-Lorena, PhD, Johns Hopkins Bloomberg School of Public Health Insectary Tour 12:30-1:30 PM Lunch 1:30-2:30 PM Transportation to IHV/ Coffee Break 2:30-4:30 PM GVN Short Course Partcipant's research presentations 4:30-5:30 PM Yuki Furuse, PhD, MD, Tohoku University, Japan New Emerging leader presentation: What can we do and what should we do during Ebola outbreak? Wednesday, August 8 9:00-10:00 AM Ab Osterhaus, DVM, PhD, University of Veterninary Medicine Hannover "One Health" 10:00-11:00 AM Stefan Sarafianos, PhD, Emory School of Medicine "Antiviral drug discovery" 11:30- 12:30 AM Robert Garry, PhD, Tulane University "Ebola and Lassa fever" 12:30-1:30 PM Lunch 1:30-2:30PM Konstantin Chumakov, FDA “Polio and other Enteroviruses” 2:30-3:30 PM Richard H.
    [Show full text]
  • 14Th Annual RBM VCWG Meeting Moevenpick Hotel Route De Pré
    14th Annual RBM VCWG Meeting Moevenpick hotel Route de Pré Bois 20, 1215 Geneva, Switzerland 30 January - 1 February 2019 Participants list # Family name First name Name of the employer Country Email 1 Aawi Agnidoufeyi Ministry of Health Togo [email protected] 2 Abdelhamid Elmahdi Muzamil Institute of Endemic Diseases, University of Khartoum Sudan [email protected] 3 Abebe Aklilu Seyoum Abt Associates United States of America [email protected] 4 Abeku Tarekegn Malaria Consortium United Kingdom [email protected] 5 Achee Nicole University of Notre Dame United States of America [email protected] 6 Adey Richard Adey Business Development GmbH Austria [email protected] 7 Agyei Samuel Asiedu Anglogold Ashanti Malaria Control Ltd. Ghana [email protected] 8 Ahmed Ayman University of Khartoum Sudan [email protected] 9 Aidenagbon Godwin Chemonics Nigeria [email protected] 10 Akim Ikupa Swiss Tropical and Public Health Institute Tanzania [email protected] 11 Akogbeto Codjo Martin Ministry of Health Benin [email protected] 12 Ali Abdullah Ministry of Health Tanzania Zanzibar [email protected] 13 Alssada Methaq National Malaria Control Programme Yemen [email protected] 14 Alvarez Ana Unitaid Switzerland [email protected] 15 Ameneshewa Birkinesh World Health Organization Republic of the Congo [email protected] 16 Arruti Errasti Begoña Goizper Group Spain [email protected] 17 Asiedu Samuel Anglogold Ashanti Malaria Control Ltd. Ghana [email protected] 18 Assan Malik Kof Anglogold Ashanti Malaria Control Ltd. Ghana [email protected] 19 Atta-Obeng Christian National Malaria Control Programme Ghana [email protected] 20 Baldini Francesco University of Glasgow United Kingdom [email protected] 21 Barasa Sheila Clinton Health Access Initiative Kenya [email protected] 22 Baud Francis Clariant Plastics & Coatings Ltd.
    [Show full text]